The RT-qPCR-based assay, which has 510(k) clearance, is designed to rapidly differentiate sepsis from systemic inflammatory response syndrome.
The contract covers all of Foundation Medicine's genomic profiling tests, including FoundationOne CDx, FoundationOne Liquid, and FoundationOne Heme.
The contract supports the development of a benchtop, fully automated platform and rapid tests to detect urinary tract infections and anthrax poisoning.
LabCorp will provide clinical reference laboratory testing services as part of the contract, whose completion date is expected to be Sept. 30, 2019.
The company will receive an upfront $9.3 million to fund a clinical trial for its NGP phenotyping platform and is eligible for an additional $36 million.
Diassess said that the funds will accelerate development of a flu test for use in the clinic and sustain development of another flu test for use in the home.
The two-year contract will be used to develop a portable prototype to quickly identify critical infectious pathogens considered threatening to war combatants.
The Phase II contract is for the further development of a portable multiplexed immunoassay system that would deliver a panel of host response biomarker results.
The five-year federal supply contract is for the company's Steripath Initial Specimen Diversion Device, which virtually eliminates blood culture contamination.
The base term for the contract, which is for medical surgical products, is 14 months with eight one-year and one 10-month option periods.